Drugs online research references
Diagn Microbiol Infect Dis. 1989 May-Jun;12(3 Suppl):93S-95S.
In vitro activity of lomefloxacin (NY-198 or SC 47111), ciprofloxacin, and erythromycin against 100 clinical Legionella strains.
Edelstein PH, Gaudet EA, Edelstein MA.
Hospital of the University of Pennsylvania, Department of Pathology, Philadelphia.
Agar dilution minimum inhibitory concentrations (MICs) of lomefloxacin (LO), ciprofloxacin (CI), and erythromycin (ER) were determined for 100 clinical isolates of Legionella using buffered charcoal yeast extract medium supplemented with alpha-ketoglutarate (BCYEa). The Legionella strains tested included 84 L. pneumophila, 2 L. micdadei, 6 L. dumoffii, 4 L. longbeachae, and one each of L. bozemanii, L. hackeliae, L. wadsworthii, and L. maceachernii. Geometric mean MICs microgram/ml were 0.56 for LO, 0.50 for CI, and 0.25 for ER. Ninety percent MICs were 1.0 for LO and CI, and 0.5 for ER. All Legionella strains except one (L. hackeliae) were inhibited by 1.0 microgram/ml of LO or CI; this strain had an Er MIC of 1.0 microgram/ml and was inhibited by 2.0 micrograms/ml of LO or CI. Control strains of Eschershia coli and Staphylococcus aureus were also tested on both BCYEa and Mueller-Hinton agar (MHA) to determine BCYEa-mediated inhibition of the antimicrobials. All three antimicrobials were inactivated in varying degrees by BCYEa. BCYEa:MHA MICs of the S. aureus control strain were 4:1 for LO and ER, and greater than 4:1 for CI. BCYEa: MHA MICs of the E. coli control strain were 4:1 for LO and CI, and unmeasurable for ER. Both LO and CI have good in vitro activity against legionella, probably greater than that measured in this study because of antimicrobial inactivation by BCYEa. Since LO is concentrated by phagocytic cells, like ER and CI, it is likely that it will be effective in the treatment of Legionnaires' disease.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2791505&dopt=Abstract
Antimicrob Agents Chemother. 1988 May;32(5):617-22.
In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents.
Wise R, Andrews JM, Ashby JP, Matthews RS.
Department of Medical Microbiology, Dudley Road Hospital, Birmingham, United Kingdom.
The in vitro activity of lomefloxacin (SC-47111; NY-198), a new difluorinated quinolone, was compared with those of ofloxacin, ciprofloxacin, fleroxacin, amoxicillin, cefuroxime, and trimethoprim against 585 recent clinical isolates and other strains with known mechanisms of resistance. The MICs of lomefloxacin against 90% of the members of the family Enterobacteriaceae, Pseudomonas aeruginosa, and staphylococci were between 0.25 and 4 micrograms/ml. Ninety percent of Neisseria sp. and Haemophilus influenzae were susceptible to less than or equal to 0.06 micrograms/ml, and streptococci (including Streptococcus pyogenes, Streptococcus pneumoniae, and enterococci) and Bacteroides fragilis were susceptible to 8 micrograms/ml. Lomefloxacin was comparable in activity to fleroxacin and ofloxacin, but it was less active than ciprofloxacin. There was cross-resistance between the quinolone group of antimicrobial agents. The protein binding of lomefloxacin was 15.4%, and serum had little effect on the activity of the compound. However, urine at pH 5.0 decreased the activity by two- to eightfold compared with that at pH 7.0
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3134843&dopt=Abstract
Antimicrob Agents Chemother. 1988 May;32(5):656-62.
In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones.
Chin NX, Novelli A, Neu HC.
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032.
Lomefloxacin (SC-47111; NY-198) is a new difluoroquinolone agent. It inhibited 90% of Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Proteus mirabilis, Morganella morganii, Proteus vulgaris, Serratia marcescens, Salmonella spp., Shigella spp., Aeromonas spp., Yersinia spp., Haemophilus influenzae, and Neisseria gonorrhoeae at less than or equal to 2 micrograms/ml. Lomefloxacin inhibited 90% of Pseudomonas aeruginosa at 4 micrograms/ml. Lomefloxacin was equal in activity to norfloxacin against Escherichia coli, Klebsiella spp., Enterobacter spp., Haemophilus influenzae, and Neisseria gonorrhoeae but was twofold less active against Proteus spp., Providencia spp., Serratia marcescens, Salmonella spp., and Shigella spp. Ofloxacin was generally 2- to 4-fold more active, and ciprofloxacin was 4- to 16-fold more active. Lomefloxacin inhibited Staphylococcus aureus, including methicillin-resistant isolates, but MICs for 90% of streptococcal species tested were 8 micrograms/ml. In the presence of 9 mM Mg2+, MICs for Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, and Pseudomonas aeruginosa were increased, as they were when they were tested in urine. A single-step increase in resistance to eightfold above the MIC occurred at a frequency of less than 10(-10), but serial transfer of bacteria in the presence of the agent produced MIC increases. Lomefloxacin had activity and properties comparable to those of many of the new quinolones.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3164987&dopt=Abstract
online pharmacies ||
Hair Million herbal formula for hair loss and hair growth ||
Amoxicillin ||
Tramadol ||
Paxil ||
Rx Drugs USA, Prescription Drugs Online Pharmacy ||
Zithromax ||
online pharmacy ||
Antibiotics and prescription medications online literature ||
Antibiotics